🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "major milestone" in the fight against drug-resistant strains of the infection, according to researchers.

A Worldwide Challenge

Gonorrhoea infections are on the rise around the world, with data suggesting more than 82 million instances annually. Notably increased rates are reported in Africa and nations within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. Within England, cases have hit a record high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The approval of new treatments for gonorrhoea is an important and timely development in the face of growing infection rates, the spread of superbugs and the highly restricted therapeutic options currently available.”

Public health authorities are particularly alarmed about the increase in treatment-resistant strains. The global health body has designated it as a "high-priority threat". Recent surveillance revealed that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Treatment Options Secure Approval

One new antibiotic, marketed under the name Nuzolvence, was authorized by the US FDA in mid-December for treating gonorrhoea. This infection can lead to major issues, including infertility. Researchers anticipate that focused deployment of this new drug will help slow the development of resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This drug, which is also used to treat UTIs, was shown in trials to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin stemmed from a unique collaborative effort for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to see it through.

“This authorization represents a significant shift in the treatment of superbug gonorrhoea, which previously has been staying ahead of antibiotic development.”

Clinical Trial Outcomes and Worldwide Availability

According to findings detailed in a prominent scientific publication, the new drug eradicated over nine in ten of cases of the STI. This establishes an similar efficacy with the typical regimen, which uses an injection and a pill. The trial involved nearly 1,000 patients from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, GARDP has the ability to make available and distribute the drug in a wide range of low-income and middle-income countries.

Doctors directly involved have shared hope. Access to a easy-to-administer therapy such as this is hailed as a "critical tool" for managing the epidemic. This is considered essential to alleviate the strain of the disease for individuals and to prevent the spread of highly drug-resistant gonorrhoea worldwide.